المؤلفون: S. Nedogoda V., A. Salasyuk S., I. Barykina N., V. Smirnova O., E. Popova A., С. Недогода В., А. Саласюк С., И. Барыкина Н., В. Смирнова О., Е. Попова А.

المصدر: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 2 (2018); 4-11 ; Качественная Клиническая Практика; № 2 (2018); 4-11 ; 2618-8473 ; 2588-0519

مصطلحات موضوعية: multicriteria analysis, drug provision, oncohematology, health technology assessment, ibrutinib: obinutuzumab, ruxolitinib, многокритериальный анализ, лекарственное обеспечение, онкогематология, оценка технологий здравоохранения, ибрутиниб, обинутузумаб, руксолитиниб

وصف الملف: application/pdf

Relation: https://www.clinvest.ru/jour/article/view/400/388; Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата. ФГБУ «Центр экспертизы и контроля качества медицинской помощи Минздрава России». Москва, 2016. [Metodicheskie rekomendatsii po provedeniyu sravnitel'noi kliniko-ekonomicheskoi otsenki lekarstvennogo preparata. FGBU «Tsentr ekspertizy i kontrolya kachestva meditsinskoi pomoshchi Minzdrava Rossii». Moscow. 2016. (In Russ).]; Методические рекомендации по многокритериальному анализу принятия решений в здравоохранении. ФГБУ «Центр экспертизы и контроля качества медицинской помощи Минздрава России». Москва, 2016. [Metodicheskie rekomendatsii po mnogokriterial'nomu analizu prinyatiya reshenii v zdravookhranenii. FGBU «Tsentr ekspertizy i kontrolya kachestva meditsinskoi pomoshchi Minzdrava Rossii». Moscow. 2016. (In Russ).]; Омельяновский В.В., Федяева В.К., Реброва О.Ю. Возможности применения многокритериального анализа для оптимизации финансирования редких заболеваний. // Фармакоэкономика. 2014;7(4):29–35. [Omelyanovskiy VV, Fedyaeva VK, Rebrova OYu. Application of Multiple-Criteria Analysis for Optimization of Financing оf Rare Diseases. Pharmacoeconomics. 2014;7(4):29–35. (In Russ).]; Сайт Министерства здравоохранения РФ. URL: https://www.rosminzdrav.ru [Sait Ministerstva zdravookhraneniya RF. Available at: https://www.rosminzdrav.ru (In Russ).]; Туркина А.Г., Новицкая Н.В., Голенков А.К. и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике. // Клиническая онкогематология. 2017;10(3):390–401. [Turkina AG, Novitskaya NV, Golenkov AK, et al. Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice. Clinical oncohematology. 2017;10(3):390–401. (In Russ).] DOI:10.21320/2500-2139-2017-10-3-390-401.; Бакиров Б.А. Клинико-патогенетическая характеристика и факторы прогноза в развитии и течении хронического лимфолейкоза, автореф. дис. на соискание ученой степени доктора медицинских наук, Санкт-Петербург, 2012. [Bakirov BA. Kliniko-patogeneticheskaya kharakteristika i faktory prognoza v razvitii i techenii khronicheskogo limfoleikoza. [dissertation] St. Petersburg; 2012 (In Russ).]; Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Что нам известно об истинной полицитемии (обзор литературы и собственные данные). // Онкогематология. 2015;3:45. [Abdulkadyrov KM, Shuvaev VA, Martynkevich IS. All we know about polycythemia vera: literature review and own experience. Oncogematology. 2015;3(10):28-42. (In Russ).] DOI:10.17650/1818-8346-2015-10-3-28-42.; Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. DOI:10.1002/ijc.29210.; Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order). Orphanet Report Series, Rare Diseases collection. 2017;1–74.; Никитин Е.А., Макарова М.В., Борисов Д.А, Поддубная И.В. Характеристика эпидемиологии, клинической картины и лечения хронического лимфолейкоза. Данные регистра лимфопролиферативных заболеваний. Тезисы Конгресс «Злокачественные лимфомы» 2015. [Kharakteristika epidemiologii, klinicheskoi kartiny i lecheniya khronicheskogo limfoleikoza. Dannye registra limfoproliferativnykh zabolevanii. EA Nikitin, MV Makarova, DA Borisov, IV Poddubnaya, Tezisy Kongress «Zlokachestvennye limfomy» 2015. (In Russ).]; Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. ASH Education Program Book. 2010;(2010)1:481-488.; URL: https://www.nice.org.uk/guidance/ta401/documents/final-appraisaldetermination-document; Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2017 год (утв. распоряжением Правительства РФ от 28 декабря 2016 г. № 2885-р). [Perechen' zhiznenno neobkhodimykh i vazhneishikh lekarstvennykh preparatov dlya meditsinskogo primeneniya na 2017 god (utv. rasporyazheniem Pravitel'stva RF ot 28 dekabrya 2016 g. № 2885-r). (In Russ).]; Rule S, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies. Br J Haematol. 2017 Nov;179(3):430–438. DOI:10.1111/bjh.14870.; Kastritis E, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126:1392–1394. DOI: https://doi.org/10.1182/blood-2015-05-647420.; URL: http://www.lymphoma.org/atf/cf/%7B0363cdd6-51b5-427b-be48-e6af871acec9%7D/HL09RELREF.PDF; Hutchings M, et al. Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Cancer Treatment Communications. 2015;4:1–11. DOI:10.1016/j.ctrc.2015.06.002.; URL: https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/typical-treatment.html; Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под руководством профессора И.В. Поддубной, профессора В.Г. Савченко. М., 2016. – 412 с. [Rossijskie klinicheskie rekomendacii po diagnostike i lecheniyu limfoproliferativnyh zabolevanij. Pod rukovodstvom professora IV Poddubnoy, professora VG Savchenko M. 2016. – 412 s. (In Russ).]; Usmani S, et al. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. The Oncologist. November. 2016;21(11):1355–1361. DOI:10.1634/theoncologist.2016-0104.; Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901.DOI: https://doi.org/10.1182/blood-2008-07-170449.; Manuel L, et al. Assessing The Level Of Resistance/Intolerance To Hydroxyurea Therapy Amongst Patients With Polycythemia Vera In Europe. Value in Health. 2015;(18)7:A436.; Badoux XC, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;(117)11:3016-3024. DOI: https://doi.org/10.1182/blood-2010-08-304683.; URL: https://seer.cancer.gov/statfacts/more.html; Smith A, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. British journal of cancer. 2015;(112)9:1575–1584.; Buske C, et al. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 201;(24)6:vi155–vi159.; Cervantes F, et al. Improving survival trends in primary myelofibrosis: an international study. Journal of Clinical Oncology. 2012;(30)24:2981-2987.; Tefferi A, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013 Sep;27(9):1874–1881. DOI:10.1038/leu.2013.163.; Sprangers MAG, Bonnetain F. EORTC QLQ-C30. Encyclopedia of Quality of Life and Well-Being Research. 2014: 1933–1935.; Hinz A, Singer S, Brähler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014 Jul;53(7):958–965. DOI:10.3109/0284186X.2013.879998.; O'Brien S, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, ASH 2016, Session: 642.; Rule S, et al. Ibrutinib versus Temsirolimus: Results From a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients With Previously Treated Mantle-Cell Lymphoma. Oral presentation presented at: the 14th International Conference on Malignant Lymphoma (ICML 2017).; Souchet L, et al. Efficacy and long‐term toxicity of the rituximab fludarabine‐cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. American journal of hematology. 2016; 91(8):782–786. DOI:10.1002/ajh.24405.; Hambley B, Caimi PF, William BM. Bortezomib for the treatment of mantle cell lymphoma: an update. Ther Adv Hematol. 2016 Aug;7(4):196–208. DOI:10.1177/2040620716648566.; Al-Sawaf O, et al. Obinutuzumab in chronic lymphocytic leukemia: Design, development and place in therapy. Drug design, development and therapy. 2017;11:295–304. DOI:10.2147/DDDT.S104869.; URL: http://www.onclive.com/conference-coverage/ash-2016/frontlineobinutuzumab-significantly-improves-pfs-in-follicular-lymphoma; Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142–152. DOI:10.1056/NEJMoa1411321.; Hájek R, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan; 31(1):107–114. DOI:10.1038/leu.2016.; Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149–57. DOI:10.1038/leu.2011.196.; Chen R, et al. Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer. 2017;8(10):1801–1808. DOI:10.7150/jca.17999.; Verstovsek S, et al. A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). 2016.; URL: https://www.nice.org.uk/guidance/ta425; Bonthapally V, et al. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. Curr Med Res Opin. 2015;31(7):1377-89. DOI:10.1185/03007995.2015.1048208.; Pro B, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017: blood-2017-05-780049; DOI: https://doi.org/10.1182/blood-2017-05-780049.; Kantarjian H, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 Mar 2;376(9):836–847. DOI:10.1056/NEJMoa1609783.; Fischer K, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 Sep 10;29(26):3559–3566. DOI:10.1200/JCO.2010.33.8061.; Brown J, et al. Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; ASH 2014, poster 3331.; Castillo JJ, et al. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic advances in hematology. 2016;(7)4:179–186.; Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101–1110. DOI:10.1056/NEJMoa1313984.; Wendtner CM, Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Feb;59(2):300–310. DOI:10.1080/10428194.2017.1330474.; Miguel JS, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055–1066. DOI:10.1016/S1470-2045(13)70380-2.; Harrison CN, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 Aug; 30(8):1701–1707. DOI:10.1038/leu.2016.148.; Vannucchi AM, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426–435. DOI:10.1056/NEJMoa1409002.; Cortes JE, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011; (118)17:4567–4576.; Dada R, Zekri J, Al Saadi R. Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opin Biol Ther. 2016 Jun;16(6):739–745. DOI:10.1080/14712598.2016.1180362.; Pro B, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18):2190–2196. DOI:10.1200/JCO.2011.38.0402.; Morel A, et al. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. Eur J Cancer. 2017 Sep;83:146–153. DOI:10.1016/j.ejca.2017.06.026.; Montillo M, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood cancer journal. 2017;(7)2:e524.; Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27–38. DOI:10.1016/S1470-2045(15)00464-7.; Hochhaus A, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May; 30(5):1044-54. DOI:10.1038/leu.2016.5.; Cortes JE, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016 Jul 10;34(20):2333–2340. DOI:10.1200/JCO.2015.64.8899.; Gopal AK, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560–568. DOI:10.1182/blood-2011-12-397893.; Burger JA, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep;15(10):1090–1099. DOI:10.1016/S1470-2045(14)70335-3.; URL: https://clinicaltrials.gov/ct2/show/results/NCT01236391?sect=Xa0156#outcome4; Stewart AK, et al. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921–3930. DOI:10.1200/JCO.2016.66.9648.; Song KW, et al. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica. 2015;(100)2:e63–e67. DOI:10.3324/haematol.2014.112557.; Mesa RA, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013 Apr 1;31(10):1285–1292. DOI:10.1200/JCO.2012.44.4489.; Mesa R, et al. Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. European journal of haematology. 2016;(97)2:192–200.; Sacha T, et al. Adherence to second line therapy with nilotinib and quality of life of patients with chronic myeloid leukemia: a multicenter prospective observational study. Haematologica. – via giuseppe belli 4, 27100 pavia, italy: ferrata storti foundation, 2017;(102):437–437.; URL: https://clinicaltrials.gov/ct2/show/record/NCT01660906?sect=X90156; Trask PC, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leukemia research. 2012;(36)4:438–442.; Ramsey SD, et al. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860–867. DOI:10.1111/bjh.14316.; Topp MS, et al. Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER). 2016.; https://www.clinvest.ru/jour/article/view/400

الاتاحة: https://www.clinvest.ru/jour/article/view/400
https://doi.org/10.24411/2588-0519-2018-10040

المؤلفون: S. Nedogoda V., A. Salasyuk S., I. Barykina N., A. Ledyaeva A., V. Tsoma V., E. Chumachek V., V. Khripaeva Y., С. Недогода В., А. Саласюк С., И. Барыкина Н., А. Ледяева А., В. Цома В., Е. Чумачек В., В. Хрипаева Ю.

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2014); 18-25 ; Медицинский Совет; № 2 (2014); 18-25 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2014-2

مصطلحات موضوعية: метаболический синдром, артериальная гипертензия, гиперурикемия, лозартан, metabolic syndrome, arterial hypertension, hyperuricemia, losartan

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/502/502; Барскова В.Г., Насонова В.А. Подагра и синдром инсулинорезистентности. Русский медицинский журнал, 2003, 23: 12-20.; Гиперурикемия, артериальная гипертензия и хроническая болезнь почек: интерпретация взаимосвязи и стратегия действий. Клиническая нефрология, 2010, 4: 4-11.; Джанашия П.Х., Диденко В.А. Является ли гиперурикемия компонентом метаболического синдрома? Российский кардиологический журнал. 2001, 1: 15-19.; Кобалава ЖД., Толкачева В.В. Мочевая кислота - независимый предиктор сердечно-сосудистых событий. Урикозурический потенциал лозартана. Клиническая фармакология и терапия, 2011, 3: 1-9.; Кобалава ЖД, Толкачева В.В. Феномен лозартан-индуцированной урикозурии и гипоурикемии: патофизиологические механизмы и клиническое значение. Часть II. Клиническая фармакология и терапия, 2003, 4: 14-17.; Лебедева М.В., Стахова Т.Ю., Балкаров И.М., Минакова Е.Г., Зайцева Л.И., Северова М.М., Шовская Т.Н. Альбуминурия, плазменная концентрация эндотелина-1 и атеросклеротическое поражение сонных артерий у больных артериальной гипертензией и гиперурикемией. Клиническая нефрология, 2009, 3: 57-61.; Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med Port, 2011, 2: 565-574.; Alderman M, Cohen H, Madhavan S, Kivlighn S. Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive. Hypertension, 1999, 34: 144-150.; Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J. Hypertens, 1998, 16: 761-769.; Athyros VG, Karagiannis A, Ganotakis ES. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin, 2011, 27: 1659-1668.; Athyros VG, Papageorgiou AA, Symeonidis AN. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. A subgroup analysis of the GREek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Angiology, 2003, 54: 679-690.; Beavers KM, Beavers DP, Serra MC. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: Findings from NHANES III. Journal of nutrition, health & aging, 2009, 3: 177-182.; Bedir А, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin Might be a Regulator of Serum Uric Acid Concentrations in Humans. Jpn Heart J, 2003, 4: 527-36.; Bonora E, Targher G, Zenere MB, Saggiani F. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord, 1996, 11: 975-980.; Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res, 2000, 87: 840-844.; Chen L, Zhu W, Chen Z, Dai H, Ren J, Chen J. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B, 2007, 8: 593-598.; Cohen E, Krause I, Fraser A, Goldberg E, Garty M. Hyperuricemia and Metabolic Syndrome: Lessons from aLarge Cohort from Israel. IMAJ, 2012, 14: 676-680.; Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health, 2004, 4: 9-15.; Cornier M, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ. The Metabolic Syndrome. Endocrine Reviews, 2008, 7; 777-822.; Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation, 2002, 106: 2085-2090.; Cuenca А, Rolda V, Marı´n F. Hypouricemic effect of statins: another pleiotropic benefit? Journal of Thoracic and Cardiovascular Surgery, 2010, 5: 1358-1359.; Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med, 1999, 131: 7-13.; Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens, 2002, 15: 590-593.; Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stressinduced insulin resistance. Antioxid Redox Signal, 2005, 7: 1040-1052.; Giacomello A, Sciascio N, Quaratino C. Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism Clinical and Experimental, 1997, 46: 1085-1089.; Goya W, Shaper G, Whincup P. Serum urate and the risk of major coronary heart disease events. Heart, 1997, 78: 147-153.; Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial Function and Oxidative Stress in Cardiovascular Diseases. Circ J, 2009, 73: 411-418.; Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. Intern Med, 2007, 46: 1353-1358.; Ho W, Tsai W, Yu K, Tsay P, Wang C, Hsu T, Kuo C. Association between endothelial dysfunction and hyperuricaemia. Rheumatology, 2010, 10: 1929-1934.; Hoieggen A, Alderman M, Kjeldsen S, Julius S, Devereux R, Faire U, Fyhrquist F, Ibsen H, Kristianson K. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International, 2004, 65: 1041-1049.; Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association Between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals. Arterioscler Thromb Vasc Biol, 2005, 25: 1038-1044.; Johnson R, Segal M, Srinivas T, Ejaz A, Mu W, Roncal C, Sa´nchez-Lozada L, Gersch M, Rodriguez-Iturbe B, Kang D, Acosta J. Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link? J Am Soc Nephrol., 2005, 16: 1909-1919.; Johnson R, Kang D, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle K, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension, 2003, 4: 1183-1190.; Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol., 2011, 8: 1887-1894.; Kansui Y, Ohtsubo T, Goto K, Sakata S, Ichishima K, Fukuhara M, Ohta Y, Matsumura K. Association of Serum Uric Acid With Blood Pressure in Japanese Men. Circulation Journal, 2011, 12: 2827-32.; Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, Ishida K, Igawa O, Shigemasa C, Somers VK. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol., 2005, 11: 1576-1580.; Koch А, Weiskirchen R, Sanson E, Zimmermann H, Voigt S, Dückers H, Trautwein C, Tacke F. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Critical Care, 2010, 14: 179-184.; Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press, 2011, 2: 104-110.; Landmesser U, Spiekermann S, Dikalov S. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxiddysmutase. Circulation, 2002, 106: 3073-3078.; Lee JM, Chang KH, Cho HM, Oh SM, Choi DP, Suh Il. Association between Serum uric acid level and metabolic syndrome. J Prev Med Public Health, 2012, 3: 181-187.; Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, He M, Tao X, Zhang W, Huang Y, Zhang Z, Qu S, Hu R. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol, 201, 10: 72.; Lyngdoh T, Marques-Vidal P, Paccaud F, Preisig M, Waeber G, Bochud M, Vollenweider P. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus. PLoS One, 2011, 5: 33-38.; Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, Matsuzawa Y. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat. Metabolism, 1998, 8: 929-933.; Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol, 2004, 7: 932-935.; Milionis H, Kakafika AI, Tsouli S, Athyros V, Bairaktari E, Seferiadis KI, Elisaf M. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. American Heart Journal, 2004, 4: 635-640.; Milionis HJ, Rizos E, Kostapanos M. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin, 2006, 22: 1123-1131.; Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J. A causal role for uric acid in fructose-induced metabolic syndrome. J Physiol Renal Physiol, 2006, 3: 625-631.; Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol, 1992, 42: 333-335.; Obermayr R, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated Uric Acid Increases the Risk for Kidney Disease. Am Soc Nephrol, 2008, 12: 2407-2413.; Oda E, Kawai R, Sukumaran V, Watanabe K. Uric acid is positively associated with metabolic syndrome but negatively associated with diabetes in Japanese men. Intern Med, 2009, 48: 1785-1791.; Ogata N, Fujimori S, Oka Y. Effects of three strong statins (atorvastatin, pitavastatin, rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids, 2010, 29: 321-324.; Oliveira E, Moreto F, Burini R. Dietary, anthropometric, and biochemical determinants of uric acid in free-living adults. Nutrition Journal, 2013, 12: 11.; Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Sari I. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens, 2006, 19: 1055-1062.; Park C, Shin WS, Kim PJ, Chang K, Kim HY, Youn HJ, Chung WS, Seung KB, Kim JH. Relationship Between Plasma Adiponectin, Retinol-Binding Protein 4 and Uric Acid in Hypertensive Patients With Metabolic Syndrome. Korean Circ J, 2011, 4: 198-202.; Puig JG, Martínez MA, Mora M. Serum urate, metabolic syndrome and cardiovascular risk factors: a population-based study. Nucleos Nucleot Nucl, 2008, 6: 620-623.; Riggiero C, Cherubini A, Ble A. Uric acid and inflammatory markers. Eur Heart J, 2006, 10: 1174-1181.; Ripley E, Hirsch А. Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients? Int J Nephrol Renovasc Dis, 2010, 3: 93-98.; Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial Circ J, 2011, 75: 1493-1505.; Salehidoost R, Aminorroaya A, Zare M. Is uric acid an indicator of metabolic syndrome in the first-degree relatives of patients with type 2 diabetes? J Res Med Sci, 2012, 11: 1005-1010.; See LC, Kuo CF, Chuang FH, Shen YM, Ko YS, Chen YM, Yu KH. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol, 2011, 30(3): 323-330.; Sweet C, Bradstreet D, Berman R. Pharmacodynamic activity of intravenous E-3174, an angiotensin II receptor antagonist, in patients with essential hypertension. Am. J. Hypertens, 1994, 7: 1035-1040.; Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2012, 2: 255-257.; Tsai WC, Huang YY, Lin CC, Li WT, Lee CH, Chen JY, Chen JH. Uric acid is an independent predictor of arterial stiffness in hypertensive patients. Heart Vessels, 2009, 5: 371-375.; Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D, Zervoudaki A, Lalos S, Kallikazaros I, Stefanadis C, Toutouzas P. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens, 2005, 3: 211-217.; Tsioufis C, Kyvelou S, Dimitriadis K, Syrseloudis D, Sideris S, Skiadas I, Katsi V, Stefanadi E, Lalos S, Mihas C, Poulakis M, Stefanadis C. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. Journal of Human Hypertension, 2011, 25: 554-559.; Tsunoda K, Abe K. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in hypertension. J. Hypertens, 1993, 6: 28-32.; Vekic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Memon L, Zeljkovic A, Bogavac-Stanojevic N, Spasic S. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis, 2009, 1: 236-242.; Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, Vettoretti S, Bezante G, Sette M, Deferrari G, Pontremoli R. Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension, 2005, 45: 991-998.; Vlachopoulos C, Xaplanteris P, Vyssoulis G, Bratsas A, Baou K, Tzamou V, Aznaouridis K, Dima I, Lazaros G, Stefanadis C. Association of Serum Uric Acid Level With Aortic Stiffness and Arterial Wave Reflections in Newly Diagnosed, Never-Treated Hypertension. American Journal of Hypertension, 2011, 24: 33-39.; Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev, 2007, 5: 251-256.; Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005, 436: 356-362.; Yoo TW, Sung KC, Shin HS, Kim BJ. Relationship Between Serum Uric Acid Concentration and Insulin Resistance and Metabolic Syndrome. Circ J, 2005, 69: 928-933.; Zapolski T, Waciński P, Kondracki B, Rychta E, Buraczyńska M, Wysokiński A. Uric acid as a link between renal dysfunction and both pro−inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiologia Polska, 2011, 4: 319-326.; Zhang ML, Gao YX, Wang X. Serum uric acid and appropriate cutoff value for prediction of metabolic syndrome among Chinese adults. J Clin Biochem Nutr, 2013, 1: 38-42.; Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric Acid and Endothelial Dysfunction in Essential Hypertension. JASN, 2006, 5:1466-1471.; https://www.med-sovet.pro/jour/article/view/502

الاتاحة: https://www.med-sovet.pro/jour/article/view/502
https://doi.org/10.21518/2079-701X-2014-2-18-25

المؤلفون: S. Nedogoda V., T. Sanina N., T. Chalyabi A., I. Barykina N., V. Tsoma V., E. Chumachek V., A. Salasyuk S., V. Khripaeva Y., V. Smirnova O., С. Недогода В., Т. Санина Н., Т. Чаляби А., И. Барыкина Н., В. Цома В., Е. Чумачек В., А. Саласюк С., В. Хрипаева Ю., В. Смирнова О.

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2014); 66-69 ; Медицинский Совет; № 11 (2014); 66-69 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2014-11

مصطلحات موضوعية: НАЖБП, метаболический синдром, ожирение, орлистат, аторвастатин, Липтонорм, NAFLD, metabolic syndrome, obesity, orlistat, atorvastatin, Liptonorm

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/672/672; https://www.med-sovet.pro/jour/article/view/672

الاتاحة: https://www.med-sovet.pro/jour/article/view/672
https://doi.org/10.21518/2079-701X-2014-11-66-69

المؤلفون: S. Nedogoda V., A. Salasyuk S., I. Barykina N., A. Ledyaeva A., V. Tsoma V., E. Chumachek V., С. Недогода В., А. Саласюк С., И. Барыкина Н., А. Ледяева А., В. Цома В., Е. Чумачек В.

المصدر: Meditsinskiy sovet = Medical Council; № 5 (2013); 60-69 ; Медицинский Совет; № 5 (2013); 60-69 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2013-5

مصطلحات موضوعية: метаболический синдром, артериальная гипертензия, тестостерон, эректиль-ная дисфункция, метформин, metabolic syndrome, hypertension, testosterone, erectile dysfunction, metformin

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1043/1023; Верткин А., Тополянский А.В. Лечение артериальной гипертензии: комбинация лекарственных средств и комбинированные препараты. РМЖ, 2010; 18(10):708-710.; Верткин АЛ., Лоран О.Б., Тополянский А.В. и др. Клиническая эффективность и влияние р-адреноблокаторов на копулятивную функцию у больных с артериальной гипертензией. Кардиология, 2002; 42(9):39-42.; Дедов И.И., Калинченко С.Ю. Возрастной андрогенный дефицит у мужчин. Практическая медицина, 2006; 236.; Исаева Е.Н. Распространенность метаболического синдрома в неорганизованной популяции с учетом разных критериев его диагностики. Казанский медицинский журнал, 2012.; Калинченко С.Ю., Лепетухин А.Е., Кварацхелия М.В., Гончаров Н.П., Шестакова М.В. Влияние заместительной гормональной терапии андрогенами на эритропоэз. Материалы IVВсероссийского Конресса «Мужское Здоровье», 12-14 ноября, Москва, 2008. D 10, стр. 35.; Консенсус российских экспертов по проблеме метаболического синдрома в Российской Федерации: определение, диагностические критерии, первичная профилактика и лечение. Профилактическая медицина, 2010; 5:27-32. '; Мазо Е.Б. и др. Влияние длительного приема варденафила на эректильную и эндотелиальную функцию у больных с артериогенной эректильной дисфункцией.; Недогода С.В., Саласюк А.С., Барыкина И.Н., Ледяева А.А., Цома В.В., Чумачек Е.В. Сравнительный анализ эффективности применения селективного b-адреноблокатора небиволола и блокатора рецепторов ангиотензина II валсартана у мужчин с артериальной гипертонией, метаболическим синдромом и эректильной дисфункцией. Кардиосоматика, 2013; 2:57-76.; Оганов Р.Г., Масленникова Г.Я. Гендерные различия кардиоваскулярной патологии. Кардиоваскулярная терапия и профилактика, 2012; 11(4):101-104.; Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). 2010.; Ротарь О.П. и др. Распространенность метаболического синдрома в разных городах РФ. Российский кардиологический журнал, 2012; 2.; Тишова Ю.А., Мсхалая Г.Ж., Калинченко С.Ю. Возрастной гипогонадизм у мужчин с метаболическим синдромом. Сахарный диабет, 2010.; Шальнова С.А. и др. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечно-сосудистых заболеваний в различных регионах России». Российский кардиологический журнал, 2012; 5 (97):6-11.; AACE Hypogonadism Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8(6):439-456.; Alhathal N., Elshal A.M., Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. Canadian Urological Association Journal, 2012; 6(4):269.; Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes, 2010; 17:224–232; Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf), 2000;53:517-22.; Bajos N, Wellings K, Laborde C, Moreau C; CSF Group. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ, 2010; 340:c2573; Bal K, Oder M, Sahin AS, et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology, 2007;69:356-.360; Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2010; 95(6):2536-2559.; Böhm M. et al. Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation, 2010; 121 (12):1439-1446.; Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol, 2011; 40:189-207.; Braun M. et al. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. International journal of impotence research, 2000; 12 (6):305-311.; Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med, 2010; 7(4 Pt 2):1627-1656.; Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med, 2011; 8:284-93.; Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care, 2009; 32:1049–1051.; Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 24 October 2010.; Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology, 2004; 55 (6):3145–52.; Davis BJ, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes, 2006; 55(2):496-505.; Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure, 2003; 12 (S2):29-34.; Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens Greenwich, 2002; 4 (6):424-32.; Fogari R. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. European journal of clinical pharmacology, 2002; 58 (3):177-180.; Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Cur Urol Rep, 2003; 4:457–65.; Gazzaruso C. et al. Erectile Dysfunction as a Predictor of Cardiovascular Events and Death in Diabetic Patients With Angiographically Proven Asymptomatic Coronary Artery DiseaseA Potential Protective Role for Statins and 5-Phosphodiesterase Inhibitors. Journal of the American College of Cardiology, 2008; 51 (21):2040-2044.; Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol, 2006; 50:940-7.; Guzik TJ, Mangalat D, Korbut R. Adipocytokines: novel link between inflammation and vascular function? J Physiol Pharmacol, 2006; 57:505-528.; Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf), 2005; 63:381-94.; Jansson PAE, et al. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes care, 1996; 19 (2):160-164.; Kim YW, Park SY, Kim JY, Huh JY. Metformin Restores the Penile Expression of Nitric Oxide Synthase in High Fat–Fed Obese Rats. J Androl, 2007; 26 (3):34–8.; Kupelian V, Shabsigh R, Araujo AB, O’Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol, 2006; 176:222–226.; Laaksonen DE, Lakka HM, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol, 2002; 156:1070-1077.; Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 2004; 27:1036-1041.; Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab, 2005; 90:712-719.; Larsen SH, Wagner G, Heitmann BL. Sexual function and obesity. Int J Obes (Lond), 2007; 31:1189-1198.; Liao CH, et al. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism. Andrology, 2013.; MacDonald AA, Herbison GP, Showell M, Farquhar CM. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update, 2010; 16:293-311.; Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med, 2009; 6:1232-1247.; Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA, 2006; 296(19):2351-2361.; Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology, 2001; 37 (5):1344-1350.; Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, et al. (2004). Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology, 145 (5):2253-2263.; Piro S, et al. Effects of metformin on oxidative stress, adenine nucleotides balance, and glucose-induced insulin release impaired by chronic free fatty acids exposure in rat pancreatic islets. Journal of endocrinological investigation, 2012; 35 (5):504.; Rochira V, Balestrieri A, Madeo B, Granata AR, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl, 2006; 27:165-175.; Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol, 2011; 165(5):675-685.; Saenz de Tejada I, Angulo J, Cellek S, et al. Physiology of erectile function. J Sex Med, 2004; 1:254-; Scarpello JHB. Improving survival with metformin: the evidence base today. Diabetes Metab, 2003; 29: 6S36-43.; Schwarz Ernst R, ed. Erectile Dysfunction. Oxford University Press, 2013.; Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res, 2009; Jan-Feb;21(1):9-23.; Steidle CP. New advances in the treatment of hypogonadism in the aging male. Rev Urol. 2003; 5(suppl 1):S34-S40.; Stellato RK, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes care, 2000; 23 (4):490-494.; Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J, 2009; 276:5755-5767.; Traish AM, Munarriz R, O’Connell L, et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl, 2003; 24:381-7.; Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med, 2010; 363:123-135.; Yassin AA, Saad F, Gooren IJ. Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia, 2008; 40:259-264.; Zhang XH, Morelli A, Luconi M, et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol, 2005; 47:409-16; discussion 416.; https://www.med-sovet.pro/jour/article/view/1043

الاتاحة: https://www.med-sovet.pro/jour/article/view/1043
https://doi.org/10.21518/2079-701X-2013-5-60-69

المؤلفون: O Zamyatina, A Ametov, I Bondar, S Hildemann, N Verbovaya, T Kiseleva, I Barykina, U Hostalek, E Shabalina, T Morugova, L Zhukova, A Vaysberg

المصدر: International Journal of Diabetes and Clinical Research. 4

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Internal medicine, Daily practice, Medicine, Extended release, business, Metformin, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::07a67e6033db7f14804a36a95ccb6af4
https://doi.org/10.23937/2377-3634/1410078

المؤلفون: D. I. Sementsov, E. I. Barykina, Igor O. Zolotovskii, Dmitry A. Korobko

المصدر: Technical Physics. 58:1194-1200

مصطلحات موضوعية: Physics, Optics, Amplitude, Physics and Astronomy (miscellaneous), Transmission (telecommunications), business.industry, Reflection (physics), Phase (waves), Waveguide (acoustics), Radiation, business, Refractive index, Magnetic field

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::767746447851d2ad398b2ed52fb67429
https://doi.org/10.1134/s1063784213080045

المؤلفون: D. I. Sementsov, E. I. Barykina, Igor O. Zolotovskii

المصدر: Journal of Communications Technology and Electronics. 57:164-169

مصطلحات موضوعية: Physics, Radiation, business.industry, Acoustics, Dynamics (mechanics), Structure (category theory), Condensed Matter Physics, Electronic, Optical and Magnetic Materials, Magnetic field, Amplitude, Optics, Transmission (telecommunications), Reflection (physics), Waveguide (acoustics), Electrical and Electronic Engineering, business, Refractive index

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ac16cdefdfc6f3f91f09831f2e61a7ab
https://doi.org/10.1134/s1064226912020015

المؤلفون: D. I. Sementsov, E. I. Barykina, Igor O. Zolotovskii

المصدر: Optics and Spectroscopy. 112:114-121

مصطلحات موضوعية: Physics, Classical mechanics, Amplitude, Wave propagation, Wave packet, Dispersion relation, Dispersion (optics), Mathematical analysis, Reflection (physics), Waveguide (acoustics), Atomic and Molecular Physics, and Optics, Electronic, Optical and Magnetic Materials, Envelope (waves)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b746e94cc7333a4248c4f3e11869fd8d
https://doi.org/10.1134/s0030400x11130042

المؤلفون: E. I. Barykina, Igor O. Zolotovskii, D. I. Sementsov

المصدر: Optics and Spectroscopy. 107:117-121

مصطلحات موضوعية: Optical fiber, Materials science, business.industry, Physics::Optics, Laser, Graded-index fiber, Atomic and Molecular Physics, and Optics, Electronic, Optical and Magnetic Materials, law.invention, Coupling (electronics), Optics, law, Dispersion (optics), Dispersion-shifted fiber, Optical radiation, Photonics, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b1d2b38bfdf8ae95de46c8506c9a2e5c
https://doi.org/10.1134/s0030400x09070170

المؤلفون: A I, BARYKINA, S S, MNUKHIN

المصدر: Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952). 60

مصطلحات موضوعية: Neurologic Manifestations, Brain Diseases, Epilepsy, Brain, Humans, Infant, Child

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::e9df061781736dd680399a1c318370af
https://pubmed.ncbi.nlm.nih.gov/13687548